Erasca (ERAS) Cash from Financing Activities (2020 - 2026)
Erasca (ERAS) posted Cash from Financing Activities of $244.7 million for Q1 2026, up 42450.26% on a QoQ basis from $575000.0 in Q4 2025, and up 741306.06% year-over-year from N/an in Q1 2025.
Erasca (ERAS) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Erasca's Cash from Financing Activities history runs 7 years deep, the most recent figure standing at $244.7 million for Q1 2026.
- Quarterly Cash from Financing Activities rose 741306.06% year-over-year to $244.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $245.7 million (up 5.1% YoY) and the FY2025 annual result came in at $1.1 million, down 99.54% from the prior year.
- Cash from Financing Activities was $244.7 million for Q1 2026 at Erasca, up from $575000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $244.7 million in Q1 2026 and bottomed at $7000.0 in Q3 2023.
- A 5-year average of $34.5 million and a median of $575000.0 in 2025 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities sank 99.87% — and 2026, when it surged 741306.06%.
- Erasca's Cash from Financing Activities stood at $96.2 million in 2022, then slumped by 99.53% to $456000.0 in 2023, then soared by 75.66% to $801000.0 in 2024, then slipped by 28.21% to $575000.0 in 2025, then soared by 42450.26% to $244.7 million in 2026.
- Business Quant data shows ERAS's Cash from Financing Activities at $244.7 million in Q1 2026, $575000.0 in Q4 2025, and $41000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Erasca | 5.89 Bn | 5.89 Bn | - | 244.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 244.66 Mn |
| Mar 31, 2026 | 244.66 Mn |
| Dec 31, 2025 | 575,000.00 |
| Dec 31, 2025 | 575,000.00 |
| Sep 30, 2025 | 41,000.00 |
| Sep 30, 2025 | 41,000.00 |
| Jun 30, 2025 | 447,000.00 |
| Jun 30, 2025 | 447,000.00 |
| Mar 31, 2025 | 33,000.00 |
| Mar 31, 2025 | 33,000.00 |
| Dec 31, 2024 | 801,000.00 |
| Dec 31, 2024 | 801,000.00 |
| Sep 30, 2024 | 21.10 Mn |
| Sep 30, 2024 | 21.10 Mn |
| Jun 30, 2024 | 211.87 Mn |
| Jun 30, 2024 | 211.87 Mn |
| Mar 31, 2024 | 6.93 Mn |
| Mar 31, 2024 | 6.93 Mn |
| Dec 31, 2023 | 456,000.00 |
| Dec 31, 2023 | 456,000.00 |